Advertisement

Familial Cancer

, Volume 18, Issue 1, pp 75–82 | Cite as

Outcome of thyroid ultrasound screening in FAP patients with a normal baseline exam

  • Marc Monachese
  • Gautam Mankaney
  • Rocio Lopez
  • Margaret O’Malley
  • Lisa Laguardia
  • Matthew F. Kalady
  • James Church
  • Joyce Shin
  • Carol A. Burke
Original Article
  • 84 Downloads

Abstract

Familial adenomatous polyposis (FAP) is a hereditary cancer syndrome associated with a substantial lifetime risk for colorectal cancer. The leading extra-colonic causes of cancer in FAP include duodenal and thyroid cancer (TC). Recent guidelines recommend annual thyroid ultrasound (TUS) screening beginning in the teenage years but the evidence to support the interval particularly in FAP patients with a normal baseline ultrasound is lacking. TUS results from FAP patients enrolled in a thyroid screening program from 2006 to 2016 and who had at least 2 TUS were reviewed. TUS findings were classified as normal, low (LR) or high risk (HR) for TC based on nodule characteristics as determined by American Thyroid Association (ATA) guidelines. We assessed the incidence of TC in patient with normal baseline TUS and factors associated with TC. 264 FAP patients were included. Baseline TUS was normal in 167, LR in 74, and HR in 24 patients. Patients were observed for a mean 4.8 years and underwent an average of 3 TUS. Patients with normal baseline TUS did not develop TC during the course of follow up of 5.1 years. TC developed in 6 patients (2.3%) all with baseline nodules; 5 in the LR group and 1 in the HR group. Factors associated with development of TC were presence of baseline nodule(s) and female sex. The development of TC in FAP patients in a TUS screening program with short term follow up is low and no FAP patient with a normal baseline TUS developed TC during observation. Annual TUS in patients with a normal baseline TUS may not be needed. Extending the screening interval to 2 years may be reasonable until nodules are detected.

Keywords

Familial adenomatous polyposis Hereditary colorectal cancer Thyroid cancer Thyroid ultrasound Cancer screening 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Burt R, Neklason DW (2005) Genetic testing for inherited colon cancer. Gastroenterology 128:1696–1716CrossRefGoogle Scholar
  2. 2.
    Kerr SE, Thomas CB, Thibodeau SN et al (2013) APC germline mutations in individuals being evaluated for familial adenomatous polyposis: a review of the Mayo Clinic experience with 1591 consecutive tests. J Mol Diagn 15:31–43CrossRefGoogle Scholar
  3. 3.
    Heiskanen I, Luostarinen T, Järvinen HJ (2000) Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol 35:1284–1287CrossRefGoogle Scholar
  4. 4.
    Groen EJ, Roos A, Muntinghe FL et al (2008) Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol 15:2439–2450CrossRefGoogle Scholar
  5. 5.
    Camiel MR, Mulé JE, Alexander LI, Benninghoff DL (1968) Association of thyroid carcinoma with Gardner’s syndrome in siblings. N Engl J Med 278:1056–1105CrossRefGoogle Scholar
  6. 6.
    Plail RO, Bussey HJR, Glazer G, Thomson JPS (1987) Adenomatous polyposis: an association with carcinoma of the thyroid. Br Surg 74:377–380CrossRefGoogle Scholar
  7. 7.
    Giardiello FM, Offerhaus GJ, Lee DH, Krush AJ, Tersmette AC, Booker SV, Kelley NC, Hamilton SR (1993) Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 34:1394–1396CrossRefGoogle Scholar
  8. 8.
    Perrier ND, Heerden JA, Goellner JR, Williams ED, Gharib H, Marchesa P, Church JM, Fazio VW, Larson DR (1998) Thyroid cancer in patients with familial adenomatous polyposis. World J Surg 22:738–743CrossRefGoogle Scholar
  9. 9.
    Feng X, Milas M, O’Malley M, LaGuardia L, Berber E, Jin J, Metzger R, Mitchell J, Shin J, Burke CA, Kalady M, Church J, Siperstein A (2015) Characteristics of benign and malignant thyroid disease in familial adenomatous polyposis patients and recommendations for disease surveillance. Thyroid 25:325–332CrossRefGoogle Scholar
  10. 10.
    Bülow S, Bulow C (1997) Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The Leeds Castle Polyposis Group. Int J Colorectal Dis 12:240–242CrossRefGoogle Scholar
  11. 11.
    Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW (2015) ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110:223–262CrossRefGoogle Scholar
  12. 12.
    Provenzale D, Gupta S, Ahnen DJ, Bray T et al (2017) Genetic/familial high-risk assessment: colorectal version 3, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw.  https://doi.org/10.6004/jnccn.2016.0108 Google Scholar
  13. 13.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133CrossRefGoogle Scholar
  14. 14.
    Herraiz M, Barbesino G, Faquin W, ChanSmutko G, Patel D, Shannon KM, Daniels GH, Chung DC (2007) Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 5:367–373CrossRefGoogle Scholar
  15. 15.
    Mazzaferri EL (1993) Management of a solitary thyroid nodule. N Engl J Med 328:553–559CrossRefGoogle Scholar
  16. 16.
    Uchino S, Ishikawa H, Miyauchi A, Hirokawa M, Noguchi S, Ushiama M, Yoshida T, Michikura M, Sugano K, Sakai T (2016) Age- and gender-specific risk of thyroid cancer in patients with familial adenomatous polyposis. J Clin Endocrinol Metab 101:4611–4617CrossRefGoogle Scholar
  17. 17.
    Kamran SC, Marqusee E, Kim MI et al (2013) Thyroid nodule size and prediction of cancer. J Clin Endocrinol Metab 98:564–570CrossRefGoogle Scholar
  18. 18.
    Jarrar AM, Milas M, Mitchell J, Laguardia L, O’Malley M, Berber E, Siperstein A, Burke C, Church JM (2011) Screening for thyroid cancer in patients with familial adenomatous polyposis. Ann Surg 253:515–521CrossRefGoogle Scholar
  19. 19.
    Steinhagen E, Guillem JG, Chang G, Salo-Mullen EE, Shia J, Fish S, Stadler ZK, Markowitz AJ (2012) The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized. Clin Colorectal Cancer 11:304–308CrossRefGoogle Scholar
  20. 20.
    Truta B, Allen B, Conrad P et al (2003) Genotype and phenotype of patients with both familial adenomatous polyposis and thyroid carcinoma. Fam Cancer 2:95–99CrossRefGoogle Scholar
  21. 21.
    Cetta F, Montalto G, Gori M et al (2000) Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. J Clin Endocrinol Metab 85:286–292Google Scholar
  22. 22.
    Cetta F, Olschwang S, Petracci M et al (1998) Genetic alterations in thyroid carcinoma associated with familial adenomatous polyposis: clinical implications and suggestions for early detection. World J Surg 22:1231–1236CrossRefGoogle Scholar
  23. 23.
    Martayan A, Sanchez-Mete L, Baldelli R, Falvo E et al (2010) Gene variants associated to malignant thyroid disease in familial adenomatous polyposis: a novel APC germline mutation. J Endocrinol Invest 33:603–606CrossRefGoogle Scholar
  24. 24.
    Ghorbanoghli Z, Bastiaansen BA, Langers AM et al (2018) Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis. J Med Genet 55:11–14CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Department of Internal MedicineCleveland ClinicClevelandUSA
  2. 2.Department of Gastroenterology and HepatologyCleveland ClinicClevelandUSA
  3. 3.Department of Quantitative Health SciencesCleveland ClinicClevelandUSA
  4. 4.Department of Colorectal SurgeryCleveland ClinicClevelandUSA
  5. 5.Sanford R. Weiss MD Center for Hereditary Colorectal NeoplasiaCleveland ClinicClevelandUSA
  6. 6.Department of Endocrine SurgeryCleveland ClinicClevelandUSA

Personalised recommendations